Evidence map›Paper›PMID 32312181›Full record

ArticleTissue engineering. Part A2020

Metformin and Inhibition of Transforming Growth Factor-Beta Stimulate

Harold Love, Rachel Evans, Harvey David Humes, Shuvo Roy, Roy Zent, Raymond Harris, Matthew Wilson, William Henry Fissell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering. Part A, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Harold LoveDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rachel EvansDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Harvey David HumesInternal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Shuvo RoyBioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Roy ZentDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Raymond HarrisDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Matthew WilsonDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
William Henry FissellDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Funding

Metabolic consequences of cystinuria and genome engineering therapeuticsI01BX004258 · VA · VETERANS HEALTH ADMINISTRATION · PI MATTHEW H WILSON · 2018 to 2026
–
BLRD VA I01 BX004258
6 · The paper itself

Abstract

Patient-oriented applications of cell culture include cell therapy of organ failure like chronic renal failure. Clinical deployment of a cell-based device for artificial renal replacement requires qualitative and quantitative fidelity of a cultured cell to its

Indexed as

MetforminTransforming Growth Factor betaCells, CulturedHumansKidney TubulesReceptor, Transforming Growth Factor-beta Type IMetforminReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, humanTransforming Growth Factor betaAMPKmetforminNKCC2renal epithelial cellsTGF-beta

Identifiers

PMID32312181
PMCPMC7580646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.